This guy is playing to the crowd, and a bit strange that a CEO would act like this (even of a small company).
MSB's trial was a failure? So he has seen the full data-set, analysed it and come to this conclusion? If so, can he call up Novartis and tell them to put their pens down and walk away from the agreement they signed with MSB.
Also, "pretty disappointing results in the clinical trials"? No idea what he has been reading, but clearly reducing mortality was better than re-hospitalization, regardless of the endpoint metrics. Seems like again he has his wires crossed.
I am guessing old Ross has been reading hotcopper comments and the share price, and is using these forums for his answers, and not the actual data. Could be some awkward moments for him coming up in future stemcell events.
(20min delay)